CA2508912A1 - Oral lactoferrin in the treatment of sepsis - Google Patents

Oral lactoferrin in the treatment of sepsis Download PDF

Info

Publication number
CA2508912A1
CA2508912A1 CA002508912A CA2508912A CA2508912A1 CA 2508912 A1 CA2508912 A1 CA 2508912A1 CA 002508912 A CA002508912 A CA 002508912A CA 2508912 A CA2508912 A CA 2508912A CA 2508912 A1 CA2508912 A1 CA 2508912A1
Authority
CA
Canada
Prior art keywords
lactoferrin
subject
composition
administered
sepsis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002508912A
Other languages
English (en)
French (fr)
Inventor
Atul Varadhachary
Karel Petrak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agennix Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2508912A1 publication Critical patent/CA2508912A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002508912A 2002-12-06 2003-12-05 Oral lactoferrin in the treatment of sepsis Abandoned CA2508912A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43139302P 2002-12-06 2002-12-06
US60/431,393 2002-12-06
US49832703P 2003-08-27 2003-08-27
US60/498,327 2003-08-27
PCT/US2003/038621 WO2004052281A2 (en) 2002-12-06 2003-12-05 Oral lactoferrin in the treatment of sepsis

Publications (1)

Publication Number Publication Date
CA2508912A1 true CA2508912A1 (en) 2004-06-24

Family

ID=32511559

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002508912A Abandoned CA2508912A1 (en) 2002-12-06 2003-12-05 Oral lactoferrin in the treatment of sepsis

Country Status (6)

Country Link
US (2) US20040152624A1 (enExample)
EP (1) EP1581243A4 (enExample)
JP (2) JP4795021B2 (enExample)
AU (2) AU2003298906A1 (enExample)
CA (1) CA2508912A1 (enExample)
WO (1) WO2004052281A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
SI2298338T1 (sl) 2002-09-16 2012-11-30 Agennix Inc Laktoferinski sestavki in postopki za zdravljenjekožnih ran
EP1581243A4 (en) * 2002-12-06 2008-01-02 Agennix Inc ORAL LACTOFERRIN FOR SEPSIS TREATMENT
AU2003296447A1 (en) * 2002-12-10 2004-06-30 Agennix Incorporated Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
AU2004289170B2 (en) * 2003-06-06 2009-12-17 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
US7183381B2 (en) * 2004-10-26 2007-02-27 Agennix, Inc. Composition of lactoferrin related peptides and uses thereof
ITMI20052351A1 (it) † 2005-12-09 2007-06-10 Microbo Srl Nuovo uso farmaceutico delle transferrine e composizioni farmaceutiche derivate
WO2007109681A2 (en) * 2006-03-20 2007-09-27 Glanbia Nutritionals (Ireland) Limited Compositions and methods for enhancing vasodilation
JP5087297B2 (ja) * 2007-03-05 2012-12-05 森永乳業株式会社 インターロイキン−１１産生促進剤
ITRM20080163A1 (it) * 2008-03-26 2009-09-27 Maurizio Acri Uso della lattoferrina per la prevenzione delle sepsi neonatali in neonati prematuri
EP2416800A1 (en) * 2010-02-25 2012-02-15 Agennix AG Oral lactoferrin in the treatment of severe sepsis
CN101829075B (zh) * 2010-04-27 2011-07-20 中国人民解放军第三军医大学第一附属医院 苦柯胺a和苦柯胺b的用途
CN105101989B (zh) * 2013-04-09 2019-10-18 加贺谷伸治 白细胞的细胞外诱捕网形成的抑制剂
WO2021222584A2 (en) * 2020-04-29 2021-11-04 The Regents Of The University Of Michigan Inhibition of sars-cov-2 viral entry through administration of lactoferrin and uses thereof
WO2022145536A1 (ko) * 2020-12-30 2022-07-07 경상대학교병원 급성 호흡 곤란 증후군 환자의 예후 예측을 위한 정보제공방법
WO2023178060A1 (en) * 2022-03-14 2023-09-21 The Children's Mercy Hospital Prophylaxis of neonatal escherichia coli sepsis

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2710997C3 (de) * 1977-03-14 1980-08-14 Dr. Karl Thomae Gmbh, 7950 Biberach 4-Alkoxy carbonylamino-phenyläthanolamine, deren Herstellung und deren Verwendung als Arzneimittel
US4977137B1 (en) * 1987-06-03 1994-06-28 Baylor College Medicine Lactoferrin as a dietary ingredient promoting the growth of the gastrointestinal tract
US5457093A (en) * 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
US5849881A (en) * 1989-05-05 1998-12-15 Baylor College Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms
US5766939A (en) * 1989-05-05 1998-06-16 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US5571697A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Texas Medical Center Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
US6100054A (en) * 1989-05-05 2000-08-08 Baylor College Of Medicine Production for recombinant lactoferrin and lactoferrin polypeptides using DNA sequences in various organisms
US5571691A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
IL94183A (en) * 1989-05-05 2003-09-17 Baylor College Medicine cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE
US5198419A (en) * 1989-12-08 1993-03-30 Immuno Japan Inc. Formulated medicines for enhancing the efficacy of beta-lactam antibiotics in prophylaxis and treatment against infectious disease due to pathogenic bacteria
US6066469A (en) * 1990-03-08 2000-05-23 Ferro Dynamics, Inc. Cloning, expression, and uses of human lactoferrin
US5240909B1 (en) * 1990-03-14 1998-01-20 Dietrich Nitsche Use of lactoferrin for treatment of toxic effects of endotoxins
EP0579830B1 (en) * 1990-11-13 1997-02-05 Santen Pharmaceutical Co., Ltd. Therapeutic agent for corneal lesion
US5564109A (en) * 1991-09-13 1996-10-08 Eastman Kodak Company Remote user interface for prioritizing and selecting from a plurality of document production peripheral devices
DE69322896T2 (de) * 1992-03-02 1999-05-27 Immuno Japan Inc., Tokio/Tokyo Verwendung von Proteinen der Transferrin/Lactoferrin-Familie zur Stimulation des Immunsystems
JPH06145068A (ja) * 1992-04-02 1994-05-24 Imuno Japan:Kk 生体防御能賦活剤・感染症治療剤・生体防御能賦活性食品
ZA932568B (en) * 1992-04-24 1993-11-12 Baylor College Midecine A Non Production of recombinant human lactoferrin
ES2145072T3 (es) * 1993-05-13 2000-07-01 American Cyanamid Co Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos.
JP3506274B2 (ja) * 1994-09-01 2004-03-15 雪印乳業株式会社 新規ペプチドおよび免疫賦活剤
JPH08165248A (ja) * 1994-12-15 1996-06-25 Nobuo Kuriiwa エンドトキシンによる炎症の抑止剤
US20020016289A1 (en) * 1995-06-01 2002-02-07 Orla M. Conneely Methods for treatment and prevention of helicobacter pylori infection using lactoferrin
US6025326A (en) * 1995-07-07 2000-02-15 Intrabiotics Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of oral mucositis
US5834424A (en) * 1995-07-12 1998-11-10 Gambit International Limited Use of lactoferrin for therapy of acute of chronic infectious diseases by the intracellular gram-positive pathogens streptococcus pyogenes and staphylococcus aureus
US6111081A (en) * 1996-05-31 2000-08-29 Baylor College Of Medicine Lactoferrin variants and uses thereof
AU6307698A (en) * 1997-02-03 1998-08-25 Pharming Bv Useful properties of human lactoferrin and variants thereof
CN1262625A (zh) * 1997-04-10 2000-08-09 阿吉尼克斯股份有限公司 乳铁蛋白在治疗过敏原诱发疾病中的应用
US5981830A (en) * 1997-05-30 1999-11-09 Schering Aktiengesellschaft Knockout mice and their progeny with a disrupted hepsin gene
US6096731A (en) * 1998-06-24 2000-08-01 Institute For Drug Research, Inc. Method for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
US20030203839A1 (en) * 1999-10-29 2003-10-30 Kruzel Marian L. Immune enhancing composition containing lactoferrin
US6613741B2 (en) * 1999-10-29 2003-09-02 Ferro Dynamics, Inc. Method for treating aseptic SIRS in humans and other animals
CN1205998C (zh) * 2000-01-14 2005-06-15 明治乳业株式会社 抗原特异性IgE抗体产生抑制剂
JP4672163B2 (ja) * 2000-03-24 2011-04-20 明治乳業株式会社 グラム陰性菌のリピドａに対する特異的抗体産生を誘導する組成物。
US7087578B2 (en) * 2000-05-24 2006-08-08 Eli Lilly And Company Formulations and methods for treating hypercoagulable states
JP4683740B2 (ja) * 2001-02-15 2011-05-18 明治乳業株式会社 炎症に伴う症状の軽減剤
US20030096736A1 (en) * 2001-05-09 2003-05-22 Kruzel Marian L. Lactoferrin for age related disorders in humans
WO2003094952A1 (en) * 2002-05-10 2003-11-20 Agennix Incorporated Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
AU2003233583A1 (en) * 2002-05-24 2003-12-12 Agennix Incorporated Oral lactoferrin in the treatment of respiratory disorders
SI2298338T1 (sl) * 2002-09-16 2012-11-30 Agennix Inc Laktoferinski sestavki in postopki za zdravljenjekožnih ran
AU2003291206A1 (en) * 2002-12-04 2004-06-23 Agennix Incorporated Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease
EP1581243A4 (en) * 2002-12-06 2008-01-02 Agennix Inc ORAL LACTOFERRIN FOR SEPSIS TREATMENT
AU2003296447A1 (en) * 2002-12-10 2004-06-30 Agennix Incorporated Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
AU2003293500A1 (en) * 2002-12-12 2004-07-09 Agennix Incorporated Lactoferrin in the reduction of pain
US7034126B2 (en) * 2003-05-14 2006-04-25 Agennix, Inc. Lactoferrin in the treatment of diabetes mellitus
AU2004289170B2 (en) * 2003-06-06 2009-12-17 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
WO2005018542A2 (en) * 2003-07-10 2005-03-03 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects

Also Published As

Publication number Publication date
EP1581243A2 (en) 2005-10-05
AU2003298906A1 (en) 2004-06-30
WO2004052281A3 (en) 2004-09-10
AU2010200210A1 (en) 2010-02-11
JP2011068666A (ja) 2011-04-07
JP4795021B2 (ja) 2011-10-19
EP1581243A4 (en) 2008-01-02
US20100210510A1 (en) 2010-08-19
US20040152624A1 (en) 2004-08-05
JP2006514111A (ja) 2006-04-27
WO2004052281A2 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
US20100210510A1 (en) Oral lactoferrin in the treatment of sepsis
Kumar et al. Iron deficiency and infection
Di Mario et al. Use of bovine lactoferrin for Helicobacter pylori eradication
ATE480623T1 (de) Bereitstellung von peptiden mit kleeblattstruktur
JP5190518B2 (ja) 免疫関連疾患を予防および治療するための組成物
JP2022176345A (ja) 敗血症の処置のためのチモシンαの使用
AU2004262446B2 (en) Method for inhibiting bacterial colonisation
US20130261048A1 (en) Composition Comprising a Peptide and an Inhibitor of Viral Neuraminidase
EP2416800A1 (en) Oral lactoferrin in the treatment of severe sepsis
US20150018268A1 (en) Multivalent synthetic compounds as antibiotic treatment
Opal et al. Recombinant human interleukin-11 in experimental Pseudomonas aeruginosa sepsis in immunocompromised animals
Ma et al. Treatment of lactoferrin and antimicrobial peptide N6 on bacterial enteritis caused by Escherichia coli in mice
EP1827476B1 (en) Use of bombesin/gastrin-releasing peptide antagonist for the treatment of sepsis, septic shock, acute lung injury or rheumatoid arthritis
JP4554150B2 (ja) 薬剤耐性菌による感染症治療剤
CN114375200A (zh) 治疗传染病的药物和方法
Zullo et al. Evolving therapy for Helicobacter pylori infection
AU722200B2 (en) Anti-helicobacter vaccine complex
US11161881B2 (en) Composition comprising a peptide and an inhibitor of viral neuraminidase
US20250368700A1 (en) Novel peptide for treating an infectious disease or condition
Vallee et al. Kinetic disposition of temafloxacin and ciprofloxacin in a murine model of pneumococcal pneumonia. Relevance for drug efficacy.
Kitamura et al. Effect of Sivelestat Sodium Hydrate in Three Patients with Septic ARDS
Zojaji et al. Role of fluoroquinolones in two-weeks triple therapy for eradication of Helicobacter pylori infection in Iranian population
JP2003128574A (ja) コンアルブミンを有効成分とする腸溶性経口組成物
JPWO2006078066A1 (ja) 経気道呼吸器感染症治療剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20131118